Literature DB >> 21184847

Livedoid vasculopathy as a coagulation disorder.

Paulo Ricardo Criado1, Evandro Ararigboia Rivitti, Mirian Nacagami Sotto, Jozélio Freire de Carvalho.   

Abstract

Livedoid vasculopathy is an occlusive cutaneous disease of the dermal vessels with pauci-inflammatory or non-inflammatory histopathology findings. It is characterized by the presence of macules or papules, erythemato-purpuric lesions located on the legs, especially on the ankles and feet, which produce ulcerations that are intensely painful and originate ivory atrophic scars called "atrophie blanche". In this review article, studies on LV from the literature are analyzed, and their etiopathogenic associations, particularly those related to the thrombophilic states, as well as the pathologic findings and therapeutic approaches applied in the difficult clinical management of these cases, are evaluated.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21184847     DOI: 10.1016/j.autrev.2010.11.008

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  10 in total

1.  Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.

Authors:  Jihane Abou Rahal; Rim S Ishak; Zaher K Otrock; Abdul-Ghani Kibbi; Ali T Taher
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

2.  Livedoid vasculopathy as a marker of systemic disease: report of two cases.

Authors:  Raquel Sucupira Andrade Lima; Gustavo Ávila Maquiné; Carolina Talhari; Isabel Cristina Lima Encarnação; Antônio Pedro Mendes Schettini; Mônica Santos
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

Review 3.  [Skin diseases due to systemic vasculitides and vasculopathies].

Authors:  S Volc; J C Maier; M Röcken
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

4.  Exacerbation of livedoid vasculopathy after coronavirus disease 2019.

Authors:  Ryoko Kawabe; Kyoko Tonomura; Yorihisa Kotobuki; Ikuko Ueda-Hayakawa; Hiroyuki Murota; Manabu Fujimoto
Journal:  Eur J Dermatol       Date:  2022-01-01       Impact factor: 2.805

5.  Exacerbation of livedoid vasculopathy after coronavirus disease 2019.

Authors:  Ryoko Kawabe; Kyoko Tonomura; Yorihisa Kotobuki; Ikuko Ueda-Hayakawa; Hiroyuki Murota; Manabu Fujimoto
Journal:  Eur J Dermatol       Date:  2022-02-15       Impact factor: 2.805

6.  A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.

Authors:  Attyla Drabik; Carina Hillgruber; Tobias Goerge
Journal:  JMIR Res Protoc       Date:  2014-12-10

7.  Dermoscopic features of livedoid vasculopathy.

Authors:  Stephen Chu-Sung Hu; Gwo-Shing Chen; Chi-Ling Lin; Yang-Chun Cheng; Yung-Song Lin
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.

Authors:  Katrin Kofler; Anke Strölin; Vanessa Geiger; Lukas Kofler
Journal:  J Cutan Med Surg       Date:  2021-03-28       Impact factor: 2.092

9.  Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Authors:  Maria Rosa Burg; Carolin Mitschang; Tobias Goerge; Stefan Werner Schneider
Journal:  Front Med (Lausanne)       Date:  2022-10-03

10.  Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin.

Authors:  Katsunobu Yoshioka; Chiharu Tateishi; Hiromi Kato; Ko-Ron Chen
Journal:  Clin Case Rep       Date:  2018-09-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.